A new study suggests patients who recover slowly from non-small-cell lung cancer (NSCLC) surgery may still benefit from delayed chemotherapy started up to four months after surgery, according to a new ...

Salvage surgery is feasible for NSCLC patients responding to targeted or immunotherapy, with a 36% pCR rate observed. The study included 30 patients, with 22 receiving immunotherapy and 8 receiving ...

Male NSCLC patients had higher complication rates, longer hospital stays, and increased costs compared to female patients. Factors like age, BMI, COPD, and smoking history were associated with worse ...

A recent analysis, evaluating an intervention in which patients with non–small cell lung cancer (NSCLC) used a wearable device to help monitor exercise post-surgery, found that participants reported ...

For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic lymph ...

Precision-targeted radiation is proving a match for surgery in early-stage lung cancer, offering patients similar long-term survival with less invasiveness, and potentially transforming how this ...

Please provide your email address to receive an email when new articles are posted on . The recurrence-free survival estimate at 5 years was 34% in stage III non-small cell lung cancer. Significant ...

Minimally invasive surgery (MIS) and stereotactic body radiotherapy (SBRT) are both used to treat stage 1 non-small cell lung cancer (NSCLC). While MIS remains the standard of care for patients with ...

(Barcelona, Spain September 9, 2025, 10:15 a.m. CEST / UTC +2) — A randomized Phase II trial from National Taiwan University Hospital reports early evidence that resecting the primary thoracic tumor ...

If you or a loved one has lung cancer, you may be interested in learning more about medicines used to treat it. One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy ...